Brill K, Schnitker J, Albring M
Schering AG, Medical Dept. Germany, Berlin.
Gynecol Endocrinol. 1990 Dec;4(4):277-86. doi: 10.3109/09513599009024982.
Oral contraception has proved to be the most efficient reversible method of fertility control for over 25 years. During this period, various investigations and epidemiological studies have suggested that some risks may be involved, but, on the other hand, a number of non-contraceptive benefits have become obvious. The results of these investigations were taken into account when new formulations had to be developed, with an aim to improving hormonal fertility control with regard to its tolerance, cycle control, and impact on metabolism. Since then, the objective of research has been to contrive new hormonal contraceptives which ensure safety to the largest possible extent, from a medical point of view, for the sake of the patient, without affecting contraceptive effectiveness. The aim to reduce side-effects connected with the use of oral contraception, as well as to lower the risks possibly involved, has obviously been achieved by extensive research. Both by devising a new substance and reducing doses, the criteria of modern low-dose oral contraception have been met, as has become evident in the course of the clinical experience gathered with Femovan.
25多年来，口服避孕药已被证明是控制生育最有效的可逆方法。在此期间，各种调查和流行病学研究表明可能存在一些风险，但另一方面，一些非避孕益处也已显现。在研发新配方时考虑了这些调查结果，目的是在耐受性、周期控制和对新陈代谢的影响方面改善激素避孕效果。从那时起，研究的目标就是研制新的激素避孕药，从医学角度出发，在不影响避孕效果的前提下，尽可能确保患者的安全。通过广泛研究，显然已经实现了减少与口服避孕药使用相关的副作用以及降低可能涉及的风险这一目标。通过设计新物质和降低剂量，满足了现代低剂量口服避孕药的标准，这在使用Femovan积累的临床经验过程中已得到证明。
